<DOC>
	<DOCNO>NCT01377194</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability Levomilnacipran ER compare placebo patient Major Depressive Disorder ( MDD ) .</brief_summary>
	<brief_title>Safety Efficacy Levomilnacipran ER ( Levomilnacipran SR ) Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Men woman , 1875 year old Currently meet DSMIVTR criterion Major Depressive Disorder The patient 's current depressive episode must least 6 week duration Women pregnant , woman breastfeed study , woman childbearing potential practicing reliable method birth control . Patients consider suicide risk Patients history meeting DSMIVTR criterion a. manic hypomanic episode b. schizophrenia psychotic disorder c. obsessivecompulsive disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>